Hims & Hers Health Inc

Hims & Hers Health Inc(HIMS)の株式分析

$29.320

+1.469 (+5.01%)終値時点

Loading chart…
高値
29.805
始値
27.710
出来高加重平均価格
28.91
出来高
12.28M
時価総額
4.30B
安値
27.600
売買代金
354.97M
EV/EBITDA(TTM)
-17.45

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.

www.forhims.com

AI分析 of Hims & Hers Health Inc (HIMS)

中立

Hims & Hers Health Inc is currently not a strong buy due to its recent performance and financial instability. The current price is $27.71, with a significant decline of 42.55% over the past year. Additionally, the RSI is at 36.78, indicating that the stock is nearing oversold territory but has not yet reversed its trend. The forward P/E ratio is high at 73.53, suggesting that the stock may be overvalued given its current earnings situation. The main risk is the ongoing class action lawsuit related to FTC allegations, which could further impact investor sentiment and stock performance.

バリュエーション指標

Hims & Hers Health Inc(HIMS)の現在の予想PERは71.94で、5年平均は18.69です。

予想PER

適正
5年平均 P/E
18.69
現在のP/E
71.94
割高
76.52
割安
-39.14

予想EV/EBITDA

適正
5年平均 EV/EBITDA
13.61
現在のEV/EBITDA
-17.45
割高
46.29
割安
-19.08

予想PSR

適正
5年平均 P/S
2.47
現在のP/S
1.61
割高
3.52
割安
1.43

Alphio AI による HIMS の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%HIMS

$133.17

シナリオ価格

基

基本

基本 · 50%HIMS

$111.56

シナリオ価格

弱

弱気

弱気 · 25%HIMS

$85.01

シナリオ価格

HIMS を保有するクジラ

T

The State of Michigan Retirement Systems

+ を保有HIMS

+5.22%

3か月リターン

S

Summit Trail Advisors, LLC

+ を保有HIMS

+2.51%

3か月リターン

C

Casdin Capital, LLC

+ を保有HIMS

-0.44%

3か月リターン

B

BIT Capital GmbH

+ を保有HIMS

-3.28%

3か月リターン

D

Divisadero Street Capital Management, LP

+ を保有HIMS

-8.80%

3か月リターン

HIMS のよくある質問 — Alphio AI が回答

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

Hims & Hers Health Inc is currently not a strong buy due to its recent performance and financial instability. The current price is $27.71, with a significant decline of 42.55% over the past year. Additionally, the RSI is at 36.78, indicating that the stock is nearing oversold territory but has not yet reversed its trend. The forward P/E ratio is high at 73.53, suggesting that the stock may be overvalued given its current earnings situation. The main risk is the ongoing class action lawsuit related to FTC allegations, which could further impact investor sentiment and stock performance.

コミュニティ

もっと見る ↗
jadeprism9715 時間前

$HIMS had a nice rally on peptides, though there is still a lot unknown about the upside potential. Peptides are really just a bonus for an already cheap stock.

もっと見る

Someone once told me about the 20SMA/50EMA crossover, so I'm always watching for it. $HIMS is tight around this crossover and looks set for a big expansion from here.

もっと見る
jade_estuary2026/10/16

HIMS stock ended a three-day decline on peptide hopes: the Trump administration is reviewing a plan that could open a $2.2B market. $HIMS

もっと見る
登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める